One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 1months
-
http://medilib.ir
- Duration of Time : 31 Day
Price : 100$- Special Price : 50$
GLP-1 and amylin receptor multiagonism with amycretin for obesity management
Reinforcing social safety for transgender and non-binary communities amidst global legislative threats
Tracking maturity of the enabling environment for clinical trials
World Bank-financed hospitals left patients with “crushing debt�
How Gavi support for RSV immunisation will advance health equity
Use of once-weekly insulins for type 1 diabetes – Author's reply
Worldwide trends in diabetes prevalence: the NCD-RisC study – Authors' reply
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial
